Kancera Ab

Ciba-geigy Corporation

Biovitrum Ab

Betagenon Ab

Baltic Bio Ab

Jan Vågberg

Styrbjörn Byström

Elisabeth Olsson

Mattias Jönsson

Håkan Mellstedt

Jacob Westman

Allan Hallett

Martin Nylöf

Meredith Williams

Per Engelhardt

Martin Henriksson

Jan-Erik Nystrom

Katarina Beierlein

Kristin Hammer

Lars Krüger

Katarina Färnegårdh

Bjorn Elman

Mikael Sellen

David Pyring

Cecilia Nilsson

Catrine Dreifeldt

Johan Schultz

Described herein is a process for the preparation of a compound of Formula I, wherein Rand Reach have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.

Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom

There is provided a compound of formula (I), wherein R, R, Qand formula (X) are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.

Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1

Process for the stereoselective preparation of chiral 2-[(hetero)arylalkylsulfanyl]pyrimidines and products obtainable therefrom

A compound of formula (I') or (I&#x2033;) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity

Process for the steroselective preparation of chiral 2- [(hetero)arylalkylsulfanyl] pyrimidines and products obtainable therefrom

There is provided a compound of formula I, wherein R, R, Qand are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.

Compound of formula (I') or (I&#x2033;) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity. 

A compound of formula (I') or (I&#x2033;) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity. 

2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity

A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer. 

Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity

According to the invention there is provided a compound of formula (I) wherein: A represents C(&#x2550;N&#x2014;W-D) or S; B represents S or C(&#x2014;NH&#x2014;W-D); when: A represents C(&#x2550;N&#x2014;W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(&#x2014;NH&#x2014;W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRR]&#x2014;; W represents &#x2014;[CRR]&#x2014; or &#x2014;C(O)&#x2014;[CRR]&#x2014;; Q represents a bond, &#x2014;N(R)&#x2014;; &#x2014;S&#x2014;, or &#x2014;O&#x2014;; Ato Arespectively represent C(R), C(R), C(R), C(R) and C(R), or, alternatively, up to two of Ato Amay independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more Rgroups, which compounds are useful in the treatment of cancer.

1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer

According to the invention there is provided a compound of formula (I) wherein: A represents C(&#x2550;N&#x2014;W-D) or S; B represents S or C(&#x2014;NH&#x2014;W-D); when: A represents C(&#x2550;N&#x2014;W-D) and B represents S then the bond between B and the NH atom is a single bond; or A represents S and B represents C(&#x2014;NH&#x2014;W-D) then the bond between B and the NH atom is a double bond; X represents -Q-[CRR]&#x2014;; W represents &#x2014;[CRR]&#x2014; or &#x2014;C(O)&#x2014;[CRR]&#x2014;; Q represents a bond, &#x2014;N(R)&#x2014;, &#x2014;S&#x2014;, or &#x2014;O&#x2014;; Ato Arespectively represent C(R), C(R), C(R), C(R) and C(R), or, alternatively, up to two of Ato Amay independently represent N; D represents phenyl, pyridyl or pyrimidinyl optionally substituted by one or more Rgroups, which compounds are useful in the treatment of cancer.

1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer

The present invention relates to compounds with the formula (I) 

Inhibitors of 11-&#x3b2;-hydroxy steroid dehydrogenase type 1

A process for the production of a 5-7 membered ring cyclic sulfonium salt compound, including a 5-7 membered ring cyclic sulfonium salt compound having a non-nucleophilic anion, is described. Members of the latter group are potentially useful as initiators for cationic polymerizations. The process comprises reacting a 1.4-, 1.5-, or 1.6-diol compound or a 5-7 membered ring cyclic ether compound with a mercapto compound and a strong protonic acid yielding the cyclic sulfonium salt compound. Some compounds described are also novel compounds per se.

Growing community of inventors

Sollentuna, Sweden

Jan Vågberg